Biogen (NASDAQ:BIIB) Price Target Increased to $363.00 by Analysts at Royal Bank of Canada
Biogen (NASDAQ:BIIB – Free Report) had its target price lifted by Royal Bank of Canada from $351.00 to $363.00 in a report issued on Thursday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Scotiabank started coverage on Biogen in a […]
More Stories
CDC Investigating Multi-State Salmonella Outbreak Linked to Backyard Poultry
By Jack Phillips The Centers for Disease Control and Prevention has said it is investigating an outbreak of salmonella bacterial...
US Allows Venezuela to Fund Maduro’s Defense After Court Challenge
By Tom Gantert The United States will ease sanctions on Venezuela to allow its regime to pay legal fees for...
Monsanto Weedkiller Case Could Upend Billions in Compensation
By Troy Myers and Jacob Burg Like countless homeowners, John Durnell of Missouri used a popular herbicide to keep his...
Planned Obsolescence: The Silent Sabotage of the Devices We Depend On
By Stephen Zogopoulos, USNN World News The Illusion of Progress Walk into any electronics store today and you’ll see the...
Shots Fired at White House Correspondents’ Dinner, Trump Evacuated, Suspect Detained
By Emel Akan and Sam Dorman President Donald Trump and First Lady Melania Trump were evacuated from the White House...
US Forces Intercept, Turn Back Iran-Linked Tanker in Arabian Sea
By Ryan Morgan A U.S. Navy helicopter intercepted and turned back toward Iran a sanctioned petrochemical tanker in the Arabian...